Publications by authors named "Semer Maksoud"

Claim this Profile
D
Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy.
Eren Aytekin, Semer Maksoud, Bakhos A Tannous, Sibel Bozdağ Pehlivan, Christian E Badr

Eur J Pharm Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arming AAV9 with a Single-Chain Fragment Variable Antibody Against PD-1 for Systemic Glioblastoma Therapy.
Semer Maksoud, Markus W Schweiger, Elie I Tabet, Tianhe Xiao, Joelle El Hokayem

Mol Neurobiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy.
Markus W Schweiger, Zohreh Amoozgar, Pierre Repiton, Robert Morris, Semer Maksoud

iScience· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cytokine/chemokine response in /HIV infection and co-infection.
Semer Maksoud, Joelle El Hokayem

Heliyon· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies.
Semer Maksoud

Mol Neurobiol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.
N Connor Payne, Semer Maksoud, Bakhos A Tannous, Ralph Mazitschek

Cell Chem Biol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.
Semer Maksoud

Mol Neurobiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation.
Christian E Badr, Cintia Carla da Hora, Aleksandar B Kirov, Elie Tabet, Romain Amante, Semer Maksoud

ACS Chem Biol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis